Health Care·Pharmaceuticals·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.17 | N/A | -22.73% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.17 | N/A | -22.73% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance without providing specific guidance. They emphasized the importance of operational stability.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on maintaining operational stability amid market challenges.
Phibro Animal Health's earnings report shows a miss on EPS, which likely contributed to the stock's slight decline of 0.83%. The lack of revenue data and guidance may lead to uncertainty among investors. Management's cautious tone suggests they are preparing for potential challenges ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SALESFORCE INC
Aug 25, 2020